Neurology
Treatment of newly diagnosed epilepsy with a single antiepileptic drug (AED) is now the favored approach for seizure management. The emergence of monotherapy as a mainstay treatment resulted from studies that demonstrated the effectiveness and advantages of a single AED in controlling seizures. Monotherapy is usually associated with fewer potential problems such as toxicity, teratogenicity, and drug-drug interactions, and is generally less expensive and easier to administer than polytherapy. Furthermore, the vast majority of patients can achieve adequate seizure control with the use of a single AED, and patients converted to monotherapy after having done poorly on polytherapy frequently show improved seizure control and experience fewer adverse effects. These findings and other advantages of monotherapy have contributed to the general failure of the concept of rational polytherapy and the acceptance of AED monotherapy as first-line treatment for most patients with epilepsy.
The expanding assemblage of AEDs provides useful new pharmacologic tools with great potential for improving patients' quality of life. However, the selection of an appropriate AED for initiation of monotherapy requires careful assessment of the risk-benefit profiles of different agents, including consideration of drug efficacy, tolerability, safety, pharmacokinetics, ease of use, and cost. Moreover, the pharmacologic management of epilepsy in special patient populations presents unique challenges and requires consideration of parameters specific to each patient. Recently published treatment recommendations provide guidance for the selection of monotherapy options for adults, the elderly, children, and women of reproductive age.
Guideline-based recommendations for the selection of AEDs can assist physicians in formulating an appropriate, safe, and effective treatment strategy. For newly diagnosed partial seizures in adults and adolescents, the American Academy of Neurology (AAN) guidelines recommend monotherapy with oxcarbazepine, lamotrigine, gabapentin, or topiramate, or with an older "standard" AED such as carbamazepine, phenytoin, phenobarbital, or valproate. The International League Against Epilepsy (ILAE) guidelines recommend carbamazepine and phenytoin as monotherapy and regard oxcarbazepine, gabapentin, lamotrigine, phenobarbital, topiramate, and vigabatrin as possibly efficacious. The AAN also recommends monotherapy with oxcarbazepine or topiramate for patients with refractory partial epilepsy. In view of the special health issues associated with epilepsy during pregnancy, AAN guidelines recommend AED monotherapy at the lowest possible dose, with drug choice based on seizure type, seizure control, and avoidance of side effects.
Management of pediatric epilepsy requires consideration of development-related issues in addition to efficacy. An expert panel of physicians treating pediatric epilepsy recently recommended oxcarbazepine and carbamazepine as treatments of choice for initial monotherapy of complex partial seizures and valproate as the treatment of choice for symptomatic myoclonic and generalized tonic-clonic seizures (except in the very young). The ILAE guidelines also recommend oxcarbazepine as initial monotherapy for newly diagnosed or untreated partial-onset seizures in children, based on level A evidence. The AAN guidelines recommend initial treatment of newly diagnosed partial epilepsy in children with standard drugs or with the newer drugs lamotrigine, gabapentin, oxcarbazepine, or topira- mate. In particular, lamotrigine is effective for children with newly diagnosed absence seizures, gabapentin is effective in the treatment of newly diagnosed partial epilepsy, and lamotrigine, oxcarbazepine, and topiramate are effective in a mixed population of newly diagnosed partial and generalized tonic-clonic seizures. Oxcarbazepine, topiramate, or lamotrigine are recommended as monotherapy in patients with refractory partial epilepsy. Of the new AEDs, oxcarbazepine is indicated by the US Food and Drug Administration for use as monotherapy in the treatment of partial seizures in children aged 4 years and older, and topiramate is indicated as initial monotherapy in patients 10 years or older with partial-onset or primary generalized tonic-clonic seizures. This supplement reviews the clinical application of AEDs approved for monotherapy and the therapeutic benefits of their use in adults and in special patient populations. The latest recommendations for use of new AEDs, strategies for conversion from polytherapy to monotherapy, issues relating to the design of monotherapy clinical trials, and animal models for the identification of new AEDs and the use of AEDs in combination are also discussed.
